In the liver, BG treatment rescued NAFLD-induced glutathione (GSH), catalase (CAT), tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 expression. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.